<DOC>
	<DOCNO>NCT00085644</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy adalimumab 40 mg give every week ( eow ) subject active ankylose spondylitis ( AS ) inadequate response , intolerant , treatment least 1 nonsteroidal anti-inflammatory drug ( NSAID ) may also fail treatment least 1 disease-modifying antirheumatic drug ( DMARD ) .</brief_summary>
	<brief_title>Human Anti-tumor Necrosis Factor ( TNF ) Monoclonal Antibody Adalimumab Subjects With Active Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subjects must &gt; = 18 year age meet Modified NY Criteria definition ankylose spondylitis ( AS ) diagnosis active AS base protocol specify criterion inadequate response intolerance &gt; = 1 nonsteroidal antiinflammatory drug ( NSAID ) able willing learn selfadminister subcutaneous ( SC ) injection Active tuberculosis , listeriosis , hepatitis B , history hepatitis C History demyelinate disease , multiple sclerosis , cancer , lymphoproliferative disease Previous antitumor necrosis factor therapy Treatment diseasemodifying antirheumatic drug ( DMARDs methotrexate , hydroxychloroquine , sulfasalazine ) Treatment intraarticular corticosteroid joint injection within 4 week study dose Biologic investigational therapy within 6 week study dose Treatment intravenous ( IV ) antibiotic within 30 day study dose Treatment oral antibiotic within 14 day study dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>